Description Semaglutide is a medication that activates the GLP-1 (glucagon-like peptide-1) receptor, which plays a crucial role in regulating blood sugar levels and appetite
This multi-receptor targeting approach has shown enhanced effectiveness in glycaemic regulation and weight loss relative to single-receptor agonists, indicating a viable route for future pharmaceutical development
Moxifloxacin, a fluoroquinolone antibiotic known to cause hepatic injury and cutaneous adverse reactions, is an uncommon culprit in the setting of prior ICI therapy but warrants vigilance for its potential to precipitate acute DILI and TEN
Patients learn why preserving muscle matters, why visceral fat is dangerous, and why the goal is fat loss with muscle preservation
Semaglutide had enormous potential across indications, but each audience brought its own expectations, motivations, and mindset